MedTrace Logo

Crocus Sativus (Saffron) and Berberis Vulgaris (Barberry Fruit) in Metabolic Syndrome

NCT01625442 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 732

Last updated 2012-06-21

No results posted yet for this study

Summary

The metabolic syndrome is associated with increased risk of cardiovascular disease and diabetes mellitus. The age-adjusted prevalence of the metabolic syndrome in the United States is 34% for men and 35% for women. Emerging alternative medicine worldwide led investigators to evaluate the efficacy of Crocus sativus (Saffron) and Berberis Vulgaris (barberry fruit) in treatment of metabolic syndrome. Serum total cholesterol, serum LDL cholesterol, serum HDL cholesterol, serum triglyceride, Fasting Blood Sugar and hematocrit measured before and after 45 days of treatment.

Conditions

Interventions

DRUG

Saffron tablet

Saffron tablets 100 mg

DRUG

Barberry tablet

Barberry tablets 200 mg

DRUG

Placebo

Placebo tablets received daily for 45 days

Sponsors & Collaborators

  • Birjand University of Medical Sciences

    lead OTHER

Principal Investigators

  • Tayyebeh Kermani, Ph.D. · Assistant proffessor of anatomy

  • Maryam Navabzadeh, M.D. · Traditional iranian medicine specialist

  • Gholamreza Sharifzadeh, M.S. · Biostatistician

  • Javad Hadinia, B.S. · Traditional iranian medicine practitioner

  • Narges Saffari, B.S. · Health technician

  • Mohammad Khodashenas Roudsari, M.D. · Assistant proffessor of internal medicine

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2011-07-31
Completion
2012-02-29

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01625442 on ClinicalTrials.gov